top of page
Antibody System Anti-HRSV-A F / Fusion glycoprotein F0 Antibody (D25)

Antibody System Anti-HRSV-A F / Fusion glycoprotein F0 Antibody (D25)

Overview
 
This monoclonal antibody specifically targets the fusion glycoprotein F0 (Protein F), an essential structural class I viral fusion machinery component encoded by Human Respiratory Syncytial Virus A (HRSV-A). The F protein is initially synthesized as an inactive precursor, F0, which undergoes proteolytic cleavage to form mature, disulfide-linked F1 and F2 subunits required for viral infectivity. This structural assembly drives host cell surface attachment and low-pH-independent membrane fusion, enabling the viral core to enter the host cytoplasm and promoting syncytia formation. Clone D25 specifically recognizes a highly conserved, prefusion-specific neutralizing epitope (Site ), making it an exceptional tool for locking the F protein in its prefusion conformation and preventing viral entry. Generated from mammalian expression systems using human hybridoma clone D25, this purified IgG1 kappa monoclonal antibody delivers high-affinity target recognition, making it an elite asset for running neutralization assays, entry inhibition modeling, and downstream vaccine development workflows targeting Human Respiratory Syncytial Virus A (strain A2).
 
DATASHEET

  • PRODUCT INFO

    Key Features and Specifications

    • Human Monoclonal Precision: Engineered from human clone D25 to deliver native-like target interactions, uniform binding kinetics, and exceptional signal-to-noise ratios without anti-species background interference.

    • Prefusion Epitope Target: Specifically binds the prefusion conformation of the F protein, facilitating highly potent neutralization profiles and viral entry inhibition analysis.

    • High Purity Profile: Verified at greater than 95 percent purity via SDS-PAGE evaluation, achieved through advanced Protein A/G affinity chromatography from cell culture supernatant.

    • Advanced Functional Performance: Validated and optimized across targeted virology methodologies, including Flow Cytometry (FCM) tracking and potent in vitro Neutralization screens.

    • Optimized Specialty Formulation: Supplied at a concentration of 1 mg/ml in a stable 100 mM Protein-Acetate (Pro-Ac), 20 mM Arginine (Arg) buffer at pH 5.0 to maintain maximum molecular and structural viability.

    Technical Specifications

    • Catalog No.: RVV02809

    • Host Species: Human

    • Clone ID: D25

    • Clonality: Monoclonal

    • Isotype: IgG1, kappa

    • Target Protein: Prefusion Fusion glycoprotein F0 (Protein F / CR9515)

    • Accession Number: P03420

    • Species Reactivity: Human respiratory syncytial virus A (strain A2)

    • Concentration: 1 mg/ml

    • Expression System: Mammalian Cells

    • Purification: Protein A/G chromatography

    • Form: Liquid solution

    • Storage Buffer: 100 mM Pro-Ac, 20 mM Arg, pH 5.0

    Alternative Names: Fusion glycoprotein F0, F, Protein F, CR9515, RSV prefusion F protein, Paramyxovirus F0 precursor.

    Applications and Recommended Dilutions

    This human monoclonal IgG1 antibody is highly suited for running functional neutralization screens, surface conformation tracking, and competitive structural validation setups within coronavirus and paramyxovirus immunity models. Investigators should utilize the following initial guidelines:

    • Neutralization Assays: Highly optimized as a therapeutic-grade control block to evaluate viral entry inhibition kinetics, plaque reduction profiles, and protective antibody screens in cell culture models.

    • Flow Cytometry (FCM): Ideal for tracking and quantifying prefusion F protein expression on the surface of infected cell lines or transfected expression hosts.

    • Note: Optimal working dilutions must be determined empirically by the end-user according to specific sample viral loads, assay configurations, and downstream detection machinery parameters.

    Handling, Reconstitution and Storage

    • Shipping: Distributed under temperature-controlled conditions on blue ice or dry ice to safeguard antibody binding integrity upon arrival.

    • Handling: Ready for immediate use. To minimize structural degradation or contamination risks, it is highly recommended to dispense the liquid solution into single-use working aliquots upon initial receipt.

    • Storage Framework:

      • Short-Term: Store at 4 degrees Celsius for up to 1 to 2 weeks.

      • Medium-Term: Store at minus 20 degrees Celsius for up to 12 months from the date of receipt.

      • Long-Term: Store at minus 80 degrees Celsius in a manual defrost freezer for maximum long-term structural viability.

      • Note: Avoid repeated freeze-thaw cycles to protect the monoclonal antibody structure from performance loss.

Heading 6

Related Products

bottom of page